A phase III randomized open-label study of single agent pembrolizumab vs physicians' choice of single agent docetaxel, paclitaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first-line standard therapy (KEYNOTE-181). NCT02564263.
Andre T et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. ASCO 2020;Abstract LBA4.
Bekaii-Saab TS et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): A randomised, multicentre, open-label, phase 2 study. Lancet Oncol 2019;20(8):1070-82. Abstract
Cho BC et al. Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study. ESMO 2019;Abstract LBA11.
Froeling FEM et al. Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death. Clin Cancer Res 2019;Abstract 25(23):7162-74. Abstract
Fukuoka S et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 2020;38(18):2053-61. Abstract
Grothey A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303-12. Abstract
Ilson DH et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: Subgroup analyses of a randomized clinical trial. JAMA Oncology 2019;6(1):e193531. Abstract
Kojima T et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. ASCO Gastrointestinal Cancers Symposium 2019;Abstract 2.
Kopetz S et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). ASCO 2020;Abstract 4039.
Liu MC et al. Response to W.C. Taylor, and C. Fiala and E.P. Diamandis. Ann Oncol 2020;31(9):1268-70. Abstract
Lorenzen S et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO. ASCO 2020;Abstract 4514.
Missiaglia E et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25(10):1995-2001. Abstract
Salvatore S et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. ASCO 2020;Abstract 4000.
Shitara K et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382(25):2419-30. Abstract
Sridharan M et al. Colorectal cancer: How emerging molecular understanding affects treatment decisions. Oncology (Williston Park) 2014;28(2):110-8. Abstract
Study of pembrolizumab (MK-3475) vs standard therapy in participants with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) stage IV colorectal carcinoma (MK-3475-177/KEYNOTE-177). NCT02563002.
Wolpin BM et al. Performance of a blood-based test for the detection of multiple cancer types. ASCO Gastrointestinal Cancers Symposium 2020;Abstract 283.